Grant: Idea to Innovation
Dalhousie University
$125,000.00
PAd-dalPhos: a new ligand class for nickel-catalyzed cross-coupling
FY 2015-16
Summary
Transition metal catalysts have proven to be effective in enabling the transformation of simple molecules into more complex, value-added products under mild conditions. Modern pharmaceutical synthesis relies heavily on the application of molecular palladium catalyst complexes to enable cross-coupling reactions that are utilized in the construction of C-C, C-N, C-O and other bonds found within sought-after drug molecules. Such catalyst complexes are comprised of a palladium-based fragment that is bound to an electron-donating ancillary ligand molecule (""ligand""). The judicious choice of ligand is crucial in terms of enabling the successful outcome of a given palladium-catalyzed reaction of interest. In this regard, a number of proprietary ligand classes have been developed and commercialized for use in the pharmaceutical industry, as well as in academic research. However, palladium is both expensive and relatively low in abundance, and ligands used with palladium are often more expensive (per-mole) than palladium itself. This provides motivation for the development entirely new classes of inexpensive ligands that enable nickel (ca. 1000X cheaper than palladium) to do the work of palladium. The requested funds are sought to accelerate the development and optimization of our novel ""PAd-DalPhos"" ancillary ligands (Fig. 1, PhosphaADamantane-DALhousie PHOSphine), and derived nickel pre-catalysts, for use in sought-after nickel-catalyzed cross-coupling reactions that are of relevance to the pharmaceutical industry, in particular amination. Having secured provisional patent protection, and in an effort to accelerate the development of this promising technology in order to promote commercialization, this proposal seeks to carry out key R&D work that will allow us to: (a) optimize our lead ligand prototype, so as to broaden our patent claims regarding composition of matter; (b) assess the utility of PAd-DalPhos ligand variants and their derived nickel pre-catalysts in enabling pharmaceutically relevant nickel-catalyzed reactions for which expensive palladium catalysts are normally employed; and (c) evaluate the shelf-life of optimized PAd-DalPhos ligand variants and their derived nickel pre-catalysts under user-friendly benchtop conditions.
Program
Idea to Innovation
Recipient
Location
Nova Scotia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
485197-2015
Name nom
Stradiotto, Mark
Department département
Chemistry
Organization id
79
Institution établissement
Dalhousie University
Province en
Nova Scotia
Province fr
Nouvelle-Écosse
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
125000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1202
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Physical sciences
Area of application fr
Sciences physiques
Research subject code
3607
Research subject group en
Inorganic chemistry
Research subject group fr
Chimie inorganique
Research subject en
Catalysis
Research subject fr
Catalyse
Partie
1
Nb partie
1
Application title
PAd-dalPhos: a new ligand class for nickel-catalyzed cross-coupling
Keyword
NSERC
Application summary
Transition metal catalysts have proven to be effective in enabling the transformation of simple molecules into more complex, value-added products under mild conditions. Modern pharmaceutical synthesis relies heavily on the application of molecular palladium catalyst complexes to enable cross-coupling reactions that are utilized in the construction of C-C, C-N, C-O and other bonds found within sought-after drug molecules. Such catalyst complexes are comprised of a palladium-based fragment that is bound to an electron-donating ancillary ligand molecule (""ligand""). The judicious choice of ligand is crucial in terms of enabling the successful outcome of a given palladium-catalyzed reaction of interest. In this regard, a number of proprietary ligand classes have been developed and commercialized for use in the pharmaceutical industry, as well as in academic research. However, palladium is both expensive and relatively low in abundance, and ligands used with palladium are often more expensive (per-mole) than palladium itself. This provides motivation for the development entirely new classes of inexpensive ligands that enable nickel (ca. 1000X cheaper than palladium) to do the work of palladium. The requested funds are sought to accelerate the development and optimization of our novel ""PAd-DalPhos"" ancillary ligands (Fig. 1, PhosphaADamantane-DALhousie PHOSphine), and derived nickel pre-catalysts, for use in sought-after nickel-catalyzed cross-coupling reactions that are of relevance to the pharmaceutical industry, in particular amination. Having secured provisional patent protection, and in an effort to accelerate the development of this promising technology in order to promote commercialization, this proposal seeks to carry out key R&D work that will allow us to: (a) optimize our lead ligand prototype, so as to broaden our patent claims regarding composition of matter; (b) assess the utility of PAd-DalPhos ligand variants and their derived nickel pre-catalysts in enabling pharmaceutically relevant nickel-catalyzed reactions for which expensive palladium catalysts are normally employed; and (c) evaluate the shelf-life of optimized PAd-DalPhos ligand variants and their derived nickel pre-catalysts under user-friendly benchtop conditions.